[{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/key-papers/blood-immune-cell.ts","type":"changed","fields":[{"field":"tldr","before":"\"An all-oral, 14-month course of a BTK inhibitor plus venetoclax beat FCR or BR chemo-immunotherapy in fit patients, offering a time-limited alternative to indefinite pills.\"","after":"\"In AMPLIFY, an all-oral, 14-month course of acalabrutinib plus venetoclax beat FCR or BR chemo-immunotherapy in fit CLL patients, offering a time-limited alternative to indefinite pills.\""}]},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","commit":"65911992ce","date":"2026-09-08","author":"Jude Gomila","message":"Key papers: haematological malignancies and immune/cell therapy","file":"src/data/key-papers/blood-immune-cell.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"tldr"},{"field":"summary"},{"field":"journal"},{"field":"year"},{"field":"authors"},{"field":"paperType"},{"field":"findings"},{"field":"whatItMeans"},{"field":"caveats"},{"field":"changedPractice"},{"field":"participants"},{"field":"links"},{"field":"cancers"},{"field":"drugs"},{"field":"targets"},{"field":"trials"},{"field":"terms"},{"field":"companies"},{"field":"related"},{"field":"bottlenecks"}]}]